Specialty Pharmacy

New therapeutic target may decrease breast cancer risk.

Top stories of the week on Specialty Pharmacy Times.

CEO of Avella Specialty Pharmacy Rebecca M. Shanahan, Esq., discusses how accountable care organizations impact specialty pharmacy.

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Palmitic acid found in olive oil, butter, cheese, milk, and meat may worsen inflammation.

The changeover to ICD-10 medical diagnosis codes could complicate tasks in emergency departments.

Treatment with dabrafenib and trametinib extends patient survival more than 2 years.

Prevalence higher among those who used illicit drugs.

Research offers enhanced method to assess effects of cancer drugs on normal and healthy cells.

Broadly neutralizing antibodies may help defend the body against HIV.

Hepatic inflammation and metabolic factors associated with hepatosteatosis in patients with chronic hepatitis C infection.

October is American Pharmacists Month, the perfect time to promote the pharmacy profession and recognize the important role of the pharmacist.

Asthma and chronic obstructive pulmonary disease (COPD) occur together at an alarming rate.

Dried plums may support retention of beneficial microbiota and patterns of microbial metabolism.

New approach may stop growth and kill cancer cells.

Excessive out-of-pocket costs can become an adverse event from treatment.

The FDA is considering approval for Sanofi's lixisenatide type 2 diabetes treatment.

Luteolin may carry significant anti-tumor effects.

Lengthening time between treatment with anti-TNF agents may improve adherence.

Sleep-wake cycle may link to exacerbated MS symptoms.

Velpatasvir is a pangenotypic NS5A inhibitor for patients with hepatitis C genotypes 1 through 6 of the virus.

Ocrelizumab found to decrease progression of clinical disability.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses the standards that illustrate quality in specialty pharmacy.

Patients treated with atezolizumab lived an average of 7.7 months longer than people treated with docetaxel chemotherapy.

MECP2 duplication syndrome is caused by duplication of genetic material in a specific region of the X chromosome.

Medical marijuana shows favorable safety profile.